Haemonetics Corporation (HAE)

(A Top Pick May 18/21, Up 6.23%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with HAE, has triggered its stop at $60. To remain disciplined, we recommend covering the position at this time. We will look for better opportunities.

(A Top Pick May 18/21, Up 19.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with HAE is progressing well. We now recommend trailing the stop (from $40) to $60. If triggered, this would all but guarantee a marginal return on the original recommended entry.

Stockchase Research Editor: Michael O'Reilly HAE stock prices took a hit in April when they announced a key client would not be renewing in 2022. The blood and plasma services company provides collection devices, disposables and software solutions. As treatments and collections resume normal activity levels post-pandemic, it is anticipated growth will return to the company. It trades at 28x earnings, compared to peers over 41x. Over 95% of the stock is held by large institutions, allowing for greater staying power. We would purchase this with stop loss at $40, looking to achieve $98 -- upside potential over 70%. Yield 0% (Analysts’ price target is $97.33)